Cargando…
Cost-efficacy analysis of the MONET trial using Spanish antiretroviral drug prices
Autores principales: | Arribas, JR, Hill, A, Garcia, I, Anceau, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113022/ http://dx.doi.org/10.1186/1758-2652-13-S4-P235 |
Ejemplares similares
-
Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
por: Pulido, F, et al.
Publicado: (2010) -
Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
por: Clumeck, N, et al.
Publicado: (2010) -
The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
por: Arribas, Jose R, et al.
Publicado: (2010) -
The duration of cost-cutting effects of price-lists
por: Schilling, Ulf Martin
Publicado: (2010) -
Cutting costs – the impact of price-lists on the cost development in the emergency department
por: Schilling, Ulf Martin
Publicado: (2009)